Reviewed August 2026 by the Corydalis Labs Technical Team. How we research and review.
Start with what is not known
The published literature on tetrahydropalmatine, the parent alkaloid, is reasonably developed. The published literature on the 13-OH derivative specifically is not. That is the honest starting position, and any supplier presenting a confident safety profile for this compound is going beyond what the record supports.
What follows is therefore framed as considerations for your own assessment, not as a safety determination. You are responsible for the safety of the products you manufacture, and that responsibility cannot be delegated to an ingredient supplier's website.
What we can tell you
Our material's identity and assay, lot by lot, with the analytical method behind those numbers. Contaminant panels on request. What we cannot tell you is how a finished product containing it will behave in your consumers — that requires work only you can commission.
Combination considerations
13-OH is used almost exclusively in blends, which means the questions that matter are combination questions:
- With mitragynine. The most common combination. Both are being consumed together; your safety assessment should treat the finished formula as the unit of analysis, not the ingredients separately.
- With stimulants. Standalone builds pair 13-OH with caffeine or botanical stimulants. Total stimulant load across the formula deserves explicit attention, particularly if the product is likely to be taken alongside other caffeinated products.
- With kava. Common in kratom-free social products. Kava carries its own well-documented considerations and its own labelling conventions in several markets.
- With absorption enhancers. Piperine increases duration and perceived effect. If you include it, your effective dose is not the number on the label in the way you might assume — factor that into your inclusion decision.
Labelling and consumer communication
Whatever your safety assessment concludes, it should show up on the label and in the marketing:
- 21+. These are adult products and should be positioned that way regardless of whether a specific statute compels it.
- Declare actives accurately, with per-serving amounts. Vague proprietary blends serve nobody and invite exactly the scrutiny this category does not need.
- No disease claims. Not in copy, not in influencer briefs, not in customer service replies. This is where enforcement actually lands. Our marketing guide covers the lines in detail.
- Do not imply intoxication or position against controlled substances.
Manufacturing controls
Product safety starts before the formula. We manufacture in our own facility under 21 CFR Part 111, with the batch records that standard requires, and every lot ships with a certificate of analysis. If you are buying material from anyone — us included — insist on that documentation and verify it independently at least once. Our quality programme.
Common questions
We are not able to make that determination for you, and we would treat any supplier who did so casually as a warning sign. The published record on this specific derivative is limited. What we provide is verified identity, assay, and contaminant testing on the material; the safety assessment for a finished product is the manufacturer’s responsibility and should be conducted properly.
We are not in a position to publish an interaction profile for this compound, because the data to support one is not there. Formulators should conduct their own assessment, pay particular attention to total stimulant load and to combinations with other centrally active ingredients, and label accordingly.
Usage guidance is a decision for the brand marketing the finished product, informed by its own safety assessment. We supply the ingredient and cannot set consumption guidance for products we do not control.
We provide certificates of analysis with identity and assay, contaminant panels on request, and our analytical method parameters. Those document what the material is. They are not a toxicological dossier and should not be presented as one.